+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 75Years
All Genders
ID07168161

Evaluating BDB-001 Injection With Standard Therapies in Adults With ANCA-Associated Vasculitis to Induce Disease Remission

Led by Staidson (Beijing) Biopharmaceuticals Co., Ltd · Updated on 2026-08-13

300

Participants Needed

65

Research Sites

45 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effectiveness of BDB-001 injection combined with cyclophosphamide followed by azathioprine, or combined with rituximab, in inducing remission in adults with active anti-neutrophil cytoplasmic antibody ANCA-associated vasculitis AAV. This phase III, randomized, double-blind trial aims to compare BDB-001 treatment against prednisone in similar combinations. The study is sponsored by Staidson Beijing Biopharmaceuticals Co., Ltd and focuses on patients aged 18 to 75 years diagnosed with granulomatosis with polyangiitis or microscopic polyangiitis. Participants are assigned to one of two groups one receives BDB-001 injection plus cyclophosphamideazathioprine or rituximab with a prednisone-matching placebo, while the other receives a placebo injection plus cyclophosphamideazathioprine or rituximab with a full starting dose of prednisone. All drugs are administered intravenously. The study measures remission at 24 weeks, with extended follow-up to evaluate sustained remission, relapse timing, kidney function, glucocorticoid toxicity, and quality of life through 48 weeks. Throughout the trial, participants undergo regular assessments using the Birmingham Vasculitis Activity Score BVAS to monitor disease activity and remission status. Additional evaluations include kidney function tests, glucocorticoid dosages, damage indices, and health-related quality of life questionnaires. Safety and treatment impact are carefully monitored, with the study lasting until February 2028. The primary outcome is the proportion of patients achieving disease remission at week 24.

CONDITIONS

Brief Title

BDB-001 Phase III Trial in ANCA-Associated Vasculitis

Research Team

A

Aiping Sun

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here